reziciclideg   Click here for help

GtoPdb Ligand ID: 14626

Synonyms: compound B201 [WO2023220640]
Compound class: Synthetic organic
Comment: Reziciclideg is the INN for a cyclin-dependent kinase degrader that was included in WHO INN Proposed List 135 (July 2026). Its structure suggests that it engages the cereblon (CRBN) E3 ubiquitin ligase. The compound is proposed as an antineoplastic agent. Note that the structure here has no specified stereo and is intended to represent the racemic mixture of isomers of the compound. The chemical structure is claimed in BioTheryX patents, for action as a CDK4/6 degrader [1-2]. Reziciclideg is predicted to be the INN for BioTheryX lead CDK4/6 PROTAC BTX-9341.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 142.38
Molecular weight 745.91
XLogP 1.73
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C(C(=O)C)C(=O)N(C2CCCC2)C3=C1C=NC(=N3)NC4=CC=C(C=N4)N5CCC(CCN6CCN(CC6)C7=CC=C(C=C7)C8CCC(=O)NC8=O)CC5
Isomeric SMILES O=C1C(C(=O)C)=C(C=2C=NC(=NC2N1C3CCCC3)NC4=NC=C(C=C4)N5CCC(CC5)CCN6CCN(C7=CC=C(C=C7)C8C(=O)NC(=O)CC8)CC6)C
InChI InChI=1S/C42H51N9O4/c1-27-35-26-44-42(47-39(35)51(32-5-3-4-6-32)41(55)38(27)28(2)52)45-36-13-11-33(25-43-36)49-19-16-29(17-20-49)15-18-48-21-23-50(24-22-48)31-9-7-30(8-10-31)34-12-14-37(53)46-40(34)54/h7-11,13,25-26,29,32,34H,3-6,12,14-24H2,1-2H3,(H,46,53,54)(H,43,44,45,47)
InChI Key CSBZXBPFGOKMKW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Chourasia AH, Erdman PE, Fung LM, Huang S, Lam I, Majeski H, Okano A, Papa P, Sapienza J, Torres E et al.. (2023)
Cdk protein degraders, pharmaceutical compositions, and therapeutic applications.
Patent number: WO2023220640A1. Assignee: BioTheryX Inc. Priority date: 10/05/2023. Publication date: 16/11/2023.
2. Chourasia AH, Majeski H, Shakya A, Liu O. (2025)
Cdk4/6 degraders for treating breast cancer.
Patent number: WO2025264885A2. Assignee: BioTheryX Inc. Priority date: 19/06/2025. Publication date: 26/12/2025.